Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nebraska Cultures is a pioneer in the probiotic industry, specializing in the manufacture and supply of premium probiotic strains and custom formulations. The company is most recognized for its flagship strain, Lactobacillus acidophilus DDS-1, which was developed through decades of research by founder Dr. Khem Shahani at the University of Nebraska. Beyond DDS-1, the company offers a range of specialty ingredients including ProDURA Bacillus coagulans and various soil-based organisms tailored for dietary supplements and functional foods. Nebraska Cultures provides comprehensive services including custom blending, stability testing, and formulation support to global health and wellness brands. In 2020, the company was acquired by Deerland Probiotics & Enzymes, further integrating its portfolio into the broader ADM Health & Wellness division.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nebraska Cultures.